Skip to content
Open access

Dabigatran Attenuates Osteoporosis by Balancing Osteoblastogenesis and Osteoclastogenesis by Targeting PRKAB1 and RELA

Aug 2026 · Research · Vol 9 · 0 citations · 63 references
Medicine

TL;DR

The findings reposition DAB as a promising therapeutic candidate for restoring osteoblast–osteoclast balance and maintaining skeletal homeostasis while establishing a novel single-molecule, dual-target pharmacological strategy and providing novel mechanistic insights for bone metabolic disease treatment.

Abstract

Imbalances between osteoblastogenesis and osteoclastogenesis represent the fundamental pathological feature of primary osteoporosis; however, safe and cost-effective therapies that simultaneously promote bone formation and suppress bone resorption are lacking. Given the central roles of runt-related transcription factor 2 and the nuclear factor κB pathway in bone remodeling, we performed a phenotypic screen of a Food and Drug Administration-approved drug library to identify dual-acting regulators of bone homeostasis and identified the orally approved anticoagulant dabigatran (DAB) as a novel candidate. In vivo, DAB administration markedly attenuated bone loss and preserved bone microarchitecture in both ovariectomized and aged mouse models of osteoporosis. In vitro, DAB not only inhibited receptor activator of nuclear factor κB ligand-induced osteoclastogenesis from bone-marrow-derived macrophages but also directly enhanced the osteogenic differentiation of bone marrow mesenchymal stem cells. Mechanistically, using limited proteolysis-coupled mass spectrometry, we identified protein kinase adenosine-monophosphate-activated noncatalytic subunit β1 and v-Rel reticuloendotheliosis viral oncogene homolog A as direct targets of DAB. In bone marrow mesenchymal stem cells, DAB binds to protein kinase adenosine-monophosphate-activated noncatalytic subunit β1 via the alanine-77 residue, leading to adenosine-monophosphate-activated protein kinase activation, subsequent mechanistic target of rapamycin complex 1 inhibition, enhanced autophagic flux, and ultimately promoted osteogenesis; in osteoclast precursors, DAB interacts with v-Rel reticuloendotheliosis viral oncogene homolog A at arginine-50, resulting in suppression of the nuclear factor κB pathway and attenuated osteoclast differentiation. Collectively, our findings reposition DAB as a promising therapeutic candidate for restoring osteoblast–osteoclast balance and maintaining skeletal homeostasis while establishing a novel single-molecule, dual-target pharmacological strategy and providing novel mechanistic insights for bone metabolic disease treatment.

Read PDF

Similar papers

Sep 2026

Cyclovirobuxine Prevents Osteoclastogenesis and Estrogen Deficiency-Induced Bone Loss by Inhibiting ROS Generation via the PI3K/AKT/FOXO1 Pathway

The results suggest that CVB suppresses osteoclastogenesis and their resorptive function through modulation of MAPK and PI3K/AKT/FOXO1 pathways and by enhancing antioxidant defense, which has potential therapeutic value for antiosteoporosis treatment.

Qiu-Fei Li, Na Hai, Jin-Deng Liao et al. · 0 citations
Sep 2026

Ricolinostat restrains osteoclastogenesis through HDAC6-associated regulation of p65 stability.

Excessive osteoclast activity is a central driver of pathological bone loss in osteoporosis; however, the mechanisms governing osteoclast differentiation remain incompletely understood, and current therapeutic options remain limited in efficacy. Therefore, we performed high-throughput drug screening to identify candida...

Hao-Fu Jiang, Wang-Zhi Li, Fang-Dan Hao et al. · 0 citations
Review Open access Aug 2026

Rewiring osteoimmune homeostasis in osteoporosis: T-cell subsets as key regulators and emerging therapeutic targets

A narrative synthesis of current evidence about the molecular mechanisms by which T-cell subsets regulate osteoporosis-related bone remodeling, the features of immune imbalance in different types of osteoporosis, T-cell-targeted intervention strategies, and translational challenges is provided to provide a theoretical...

Yuan Gong, Wen-Xing Zeng, Yi-Tao Liao et al. · 0 citations
Open access Aug 2026

Urolithin A Alleviates Osteonecrosis and Is Associated With Regulation of SIRT3 in Osteoclasts

Background: Urolithin A (UA) is a safe and promising therapeutic strategy for aging-related disorders, including osteoporosis. Sirtuin 3 (SIRT3) has been reported as a potential modulator of bone-joint pathologies such as osteoclast activation. However, whether UA affects osteoclast activation and function through SIRT...

Yi Xue, Dong-Hua Fan, Pu Ying et al. · 0 citations
Aug 2026

Naringenin alleviates age-related bone loss by targeting Runx2.

BACKGROUND AND PURPOSE Senile osteoporosis presents a significant and growing health burden. Currently, no pharmacological agents are specifically approved for this condition. The dietary flavonoid naringenin (NAR) exhibits osteoprotective potential; however, its efficacy and direct molecular target in the context of s...

Chuanxin Sun, Yuke He, Fu Xiao et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.